» Authors » Renata Veselska

Renata Veselska

Explore the profile of Renata Veselska including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 58
Citations 751
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Veselska R, Sirucek J, Kure J
BMC Med Ethics . 2024 Dec; 25(1):153. PMID: 39710660
Background: The primary objective of this study was to conduct a comprehensive questionnaire survey on the practices of research ethics committees reviewing academic research projects in Czechia. The study aims...
2.
Curylova L, Zambo I, Neradil J, Kyr M, Jurackova N, Pavlova S, et al.
Cell Oncol (Dordr) . 2024 Dec; 47(6):2317-2334. PMID: 39630408
Purpose: Pediatric sarcomas are bone and soft tissue tumors that often exhibit high metastatic potential and refractory stem-like phenotypes, resulting in poor outcomes. Aggressive sarcomas frequently harbor a disrupted p53...
3.
Pleskac P, Fargeas C, Veselska R, Corbeil D, Skoda J
Cell Mol Biol Lett . 2024 Mar; 29(1):41. PMID: 38532366
Prominin-1 (CD133) is a cholesterol-binding membrane glycoprotein selectively associated with highly curved and prominent membrane structures. It is widely recognized as an antigenic marker of stem cells and cancer stem...
4.
Prainsack B, do Ceu Patrao Neves M, Sahlin N, Biller-Andorno N, Laukyte M, Lukow P, et al.
Lancet Reg Health Eur . 2023 Jan; 24:100553. PMID: 36643663
No abstract available.
5.
Krchniakova M, Paukovcekova S, Chlapek P, Neradil J, Skoda J, Veselska R
Front Pharmacol . 2022 Sep; 13:976955. PMID: 36160437
Tyrosine kinase inhibitors (TKIs) are frequently used in combined therapy to enhance treatment efficacy and overcome drug resistance. The present study analyzed the effects of three inhibitors, sunitinib, gefitinib, and...
6.
Paukovcekova S, Krchniakova M, Chlapek P, Neradil J, Skoda J, Veselska R
Int J Mol Sci . 2022 Aug; 23(15). PMID: 35955683
Anticancer therapy by anthracyclines often leads to the development of multidrug resistance (MDR), with subsequent treatment failure. Thiosemicarbazones have been previously suggested as suitable anthracycline partners due to their ability...
7.
Macsek P, Skoda J, Krchniakova M, Neradil J, Veselska R
Int J Mol Sci . 2022 Jan; 23(1). PMID: 35008802
Despite constant advances in the field of pediatric oncology, the survival rate of high-risk neuroblastoma patients remains poor. The molecular and genetic features of neuroblastoma, such as amplification and stemness...
8.
Woods A, Berlow N, Ortiz M, Cruz F, Siddiquee A, Coutinho D, et al.
Pediatr Blood Cancer . 2021 Oct; 69(2):e29401. PMID: 34693628
Background: Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms tumor have been described: tumors lacking anaplasia (the favorable subtype) and tumors displaying anaplastic...
9.
Mahdal M, Neradil J, Mudry P, Paukovcekova S, Zambo I, Urban J, et al.
Cancers (Basel) . 2021 Jul; 13(14). PMID: 34298757
Giant-cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new...
10.
Ramos H, Soares M, Silva J, Raimundo L, Calheiros J, Gomes C, et al.
Cell Rep . 2021 Apr; 35(2):108982. PMID: 33852837
Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53 activity has become one of the most appealing anticancer therapeutic strategies. Here, we disclose the p53-activating...